

## University of Groningen

### (Un)Healthy in the city

Zijlema, Wilma

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2016

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Zijlema, W. (2016). *(Un)Healthy in the city: Adverse health effects of traffic-related noise and air pollution*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

# 5

## How to assess common somatic symptoms in large-scale studies: a systematic review of questionnaires

Wilma L. Zijlema, Ronald P. Stolk, Bernd Löwe, Winfried Rief, BioSHaRE, Peter D. White, Judith G.M. Rosmalen

*Journal of Psychosomatic Research* 2013 Jun;74(6):459-68

## **ABSTRACT**

### **Objective**

Many questionnaires for assessment of common somatic symptoms or functional somatic symptoms are available and their use differs greatly among studies. The prevalence and incidence of symptoms are partially determined by the methods used to assess them. As a result, comparison across studies is difficult. This article describes a systematic review of self-report questionnaires for somatic symptoms for use in large-scale studies and recommends two questionnaires for use in such studies.

### **Methods**

A literature search was performed in the databases Medline, PsycINFO and EMBASE. Articles that reported the development, evaluation, or review of a self-report somatic symptom measure were included. Instrument evaluation was based on validity and reliability, and their fitness for purpose in large scale studies, according to the PhenX criteria.

### **Results**

The literature search identified 40 questionnaires. The number of items within the questionnaires ranged from 5 to 78 items. In 70% of the questionnaires, headaches were included, followed by nausea/upset stomach (65%), shortness of breath/breathing trouble (58%), dizziness (55%), and (low) back pain/backaches (55%). Data on validity and reliability were reported and used for evaluation.

### **Conclusion**

Questionnaires varied regarding usability and burden to participants, and relevance to a variety of populations and regions. Based on our criteria, the Patient Health Questionnaire-15 and the Symptom Checklist-90 somatization scale seem the most fit for purpose for use in large-scale studies. These two questionnaires have well-established psychometric properties, contain relevant symptoms, are relatively short, and are available in multiple languages.

## INTRODUCTION

A symptom is a self-reported bodily sensation or mental experience that is perceived by a person as a change from normal health [1]. A British study showed that the mean number of symptoms reported in the general population is between three and four in the last two weeks [2] and a recent Norwegian study found a strong association between the number of symptoms and functional status [3]. Symptoms may be mediated by a change in bodily function or may be associated with disease. It is commonly the case that a symptom cannot be conclusively explained by organic pathology. These symptoms are referred to as functional somatic symptoms (FSS). The more symptoms reported, the more likely symptoms are functional in nature [4,5]. Patients who frequently complain of physical symptoms that either lack a demonstrable organic basis, or that are judged to be in excess of what would be expected based on medical findings, are thought to be suffering from the process of somatization. This view is qualified by the knowledge that future research may find medical explanations for some of these FSS. Somatization refers to a tendency to experience and communicate somatic distress in response to psychosocial stress and seek medical help for it [6]. Functional somatic symptoms are common [7-9], disabling [10-12], costly [13], and patients often feel misunderstood, guilty and even ashamed [14].

The occurrence of symptoms is often assessed by using a self-report symptom questionnaire. Many different questionnaires are available and the use of these questionnaires differs greatly among current studies, complicating the comparison of studies. Firstly, the questionnaires differ greatly in the number of symptoms questioned. Secondly, there is a large variety in the type of symptoms included in the questionnaires. Previous studies have suggested that certain types of symptoms cluster together [15-17]. Although not found in all studies, the following four clusters are commonly reported: cardiopulmonary (including autonomic symptoms), gastrointestinal, musculoskeletal, and general symptoms. Thirdly, some of these questionnaires assess symptoms in general, while others focus on medically unexplained symptoms. Being certain that a symptom is medically unexplained can be difficult, has low inter-rater reliability [18,19], and would be impossible to assess in large-scale studies. Fourthly, the time frame of assessment varies largely. Some questionnaires are based on life-time symptoms; but several researchers suggest that recall of lifetime symptoms is unreliable and inconsistent [20-22]. Others address time frames of between a week and a month. Fifthly, some questionnaires enquire only about the categorical presence of symptoms, while others inquire about symptom severity; both symptom diversity and severity may be important [9].

Given the heterogeneity of scales with respect to content, scaling, and dimensionality, severity scores from different FSS or somatic symptom scales are incomparable. Using cut-off-scores, each scale identifies a unique subgroup that differs in various aspects from subgroups identified by other scales. It would be very useful to have a gold standard measure for the assessment of both FSS and somatic symptoms in general in large-scale studies. Agreement regarding the use of such an instrument can facilitate systematic comparisons or meta-analytical studies and thereby contribute to the understanding of the etiology of functional somatic symptoms.

To the best of our knowledge, an overview of the currently available symptom questionnaires has not been reported. This article describes a systematic review of self-report questionnaires for common somatic symptoms for use in large-scale studies. It will conclude with a recommendation for which symptom questionnaires are the best to use. This recommendation will be based on validity and reliability on the one hand, and applicability in large-scale studies on the other hand. The first aspects will be evaluated in terms of number and types of symptoms included, the response scale, time frame covered, and data on validity and reliability. The second aspects will be evaluated using the PhenX (Phenotypes and eXposures) criteria, according to which a measure should be well-established; easy in its use; of low burden to participants; relevant for future use; and applicable to a variety of populations and regions [23].

## **METHODS**

### **Search strategy**

A literature search was performed in the databases Medline, EMBASE and PsycINFO on the 15th of October 2012. A search term was formulated for searching the databases, which contained a combination of somatoform disorder or synonyms and questionnaire or synonyms and symptoms. For Medline, the following search term was used: (“somatoform disorders/classification”[MeSH Major Topic] OR “somatoform disorders/diagnosis”[MeSH Major Topic] OR “somatoform disorders/epidemiology”[MeSH Major Topic] OR “functional somatic symptoms” [Title/Abstract]) AND (questionnaire[Title/Abstract] OR screen\*[Title/Abstract] OR “self report”[Title/Abstract] OR “index”[Title/Abstract]) AND symptoms. For EMBASE and PsycINFO comparable search terms were used. The search was conducted without language restrictions. Personal files of the authors were also reviewed for relevant articles. Additional searches were performed using the

search engine Google and the authors of the questionnaires were contacted to obtain supplemental information of the symptom questionnaires, if needed.

### **Screening and selection procedure**

The titles and abstracts of the retrieved articles were screened by two independent researchers. The articles were chosen for the development, evaluation, or review of somatic symptom or somatization questionnaires. Additionally, the measure had to be a self-report symptom checklist. Interviews were excluded, as these are not suitable for use in large studies. Furthermore, the questionnaires chosen had to include symptoms from more than one symptom cluster; not just symptoms of the gastrointestinal tract or cardiopulmonary system. When the symptom questionnaire was a sub-scale derived from a larger questionnaire, the symptom subscale had to have been separately validated and used. There were no criteria for the target population of the questionnaire. Discrepancies between the two researchers were resolved by consensus. Full articles were then obtained for all included studies. Based on the full text, articles that still fulfilled the inclusion criteria were included in the review.

### **Data extraction**

Authors, year of publication, name of questionnaire, purpose of questionnaire, questionnaire instructions, list of symptoms, answering scale, and language of questionnaire, were extracted for every questionnaire. Data extraction from papers describing the validation of a questionnaire also included validity data, characteristics about the population used (clinical or general, gender and age distribution, nationality or race), and number of participants. Data extraction from articles written in languages other than English was done by native speakers.

### **Instrument evaluation**

The questionnaires were evaluated according to the following criteria; the first set of criteria concerned the validity and reliability of the instrument. Firstly, we examined the type of symptoms included. We assumed that the proportion of questionnaires including a specific symptom reflected expert knowledge on the importance of that specific symptom for the underlying construct. To ensure that the questionnaire was not too restrictive with regard to the type of symptom, we evaluated whether the questionnaires included at least one symptom from each of the following symptom clusters identified in previous studies [15-17]: cardiopulmonary (including autonomic symptoms), gastrointestinal, musculoskeletal, and general symptoms. Since being certain that a symptom is medically unexplained can be difficult, has low inter-rater reliability [18,19], and would be


impossible to assess in large-scale studies, we proposed that self-report symptom questionnaires should preferably question symptoms in general, as opposed to medically unexplained symptoms. Secondly, we noted the time frame covered by the questionnaire. Studies have shown that the recall of lifetime symptoms is unreliable [20-22]. We therefore do not recommend the use of lifetime as a recall period. Thirdly, we assessed the response scale. We looked at the format of the questionnaires' responses: severity, frequency, and the number of response categories. Fourthly, we recorded the psychometric characteristics. The internal consistency was assessed, which reflects whether items in a questionnaire are correlated, thus measuring the same concept. The factor structure of a questionnaire indicates which symptom clusters are present within the questionnaire. Correlations of the symptom questionnaire with other related constructs, for example health anxiety and illness behavior, also inform the validity of the questionnaire. In addition, the test-retest reliability of a questionnaire is an important indicator for the stability of the questionnaire. It is likely that symptom reporting fluctuates over time. Therefore, short time intervals for test-retest reliability would be most appropriate, and an interval of 3-4 weeks is commonly used [24]. We therefore chose to report the test-retest reliability for time intervals no longer than 1 month.

The second set of criteria concerns the applicability to large-scale studies, which we based on the PhenX (Phenotypes and eXposures) criteria [23]. PhenX is an initiative that aims to reach consensus about which measures should be used in large-scale genomic studies, but also applies to other large-scale studies. Within the PhenX initiative several criteria for the selection of well-established, low-burden, high-quality measures were developed. Firstly, the questionnaire should be a well-established measure (used repeatedly over time and coming from highly regarded sources). Secondly, the questionnaire can be used by scientists who do not have expertise in that specific domain. Thirdly, the questionnaire should be a relatively low burden to participants and investigators. Fourthly, the questionnaire should be relevant for the near future. Fifthly, the questionnaire should be applicable to a variety of populations (different ethnic groups, ages and gender); and sixthly, the questionnaire should not be constricted to a particular country/region [23].

## RESULTS

### Search results

The search retrieved a total of 1214 articles. 1136 articles were excluded, of which 127 were duplicates; 928 were not about FSS, somatization or were not self-report questionnaires; 5 were about questionnaires with a relevant subscale, but the subscale was not separately validated and used; and 76 were about questionnaires already included, but contained no validity data. Additionally, 21 articles were added from our personal files. Thus, 99 articles were included, describing 40 questionnaires (figure 1).



**Figure 1.** Flow chart of systematic review process

### Part 1: Validity and reliability

#### *Evaluation of questionnaires*

Table 1 shows the types of questionnaires that were reported within the 99 included articles. The 40 questionnaires showed considerable overlap in their aims

and sometimes even in their abbreviations (e.g., the PHQ and the BSI each refer to two different instruments). Furthermore, some of the questionnaires are adapted versions of other questionnaires. For example, the SOMS has several versions which differ in the number of items and the time frame for symptom recall, and the BSI-6 is a shortened version of the SCL-90 SOM. The majority of questionnaires assessed the frequency of symptoms (57%). Symptom severity was assessed by 28% of the questionnaires, and 15% assessed both frequency and severity.

**Table 1.** Overview of the 40 symptom questionnaires and their properties<sup>a</sup>

Questionnaire	Items	Domain assessed	Scale	Time frame	Target population	Multiple languages
<b>4DSQ [25]</b>	16 <sup>b</sup>	somatization	5 categories: <i>no to very often or constantly</i>	past week	primary care patients	yes
<b>ASR [26]</b>	11 <sup>b</sup>	somatic complaints	3 categories: <i>not true to very true or often true</i>	past six months	adults	yes
<b>BDS Checklist [27]</b>	25	BDS; pattern of symptoms rather than a simple symptom count (based on SCAN interview)	5 categories: <i>not at all to a lot</i>	past month	patients	yes
<b>BSI-6 [28]</b>	6 <sup>b</sup>	somatization	5 categories: <i>not at all to always</i>	past week	adolescents and adults	yes
<b>BSI [29,30]</b>	44	somatic symptoms associated with anxiety and depression	3 categories: <i>symptom absent to present on more than 15 days during the past month</i>	past month	patients	yes
<b>Cambodian SSI [31]</b>	23	somatic symptoms and cultural syndromes; with a 12-item somatic subscale and an 11-item syndrome subscale	5 categories: <i>not at all to extremely</i>	past month	traumatized Cambodian refugees	yes
<b>C-PSC [32]</b>	12	psychosomatic symptoms	frequency, 5 categories: <i>not a problem to every day</i> ; severity, 5 categories: <i>not a problem to very, very bad</i>		children	no
<b>CSI [33,34]</b>	36	intensity of somatic complaints	4 categories: <i>not at all to a whole lot</i>	past two weeks	children	no
<b>FBL [35]</b>	78	somatic complaints	frequency, 5 categories: <i>almost every day to almost never</i> ; intensity, 5 categories: <i>very strongly to insensitive</i>	'lately'		yes

**Table 1.** Overview of the 40 symptom questionnaires and their properties<sup>a</sup> (continued)

Questionnaire	Items	Domain assessed	Scale	Time frame	Target population	Multiple languages
<b>GBB-24</b> [36]	24	physical complaints	5 categories: <i>never to severe</i>		patients and general population	yes
<b>GSL</b> [37]	37	psychosomatic stress symptoms	4 categories: <i>never to constantly</i>			no
<b>HEALTH-49</b> [38]	7 <sup>b</sup>	somatoform complaints	5 categories: <i>not at all to very much</i>	past two weeks	primary care patients	yes
<b>ICD-10 Symptom List</b> [39,40]	14	somatization disorder	<i>yes/no</i>	past two years	patients	yes
<b>Kellner's SQ</b> [41]	17 <sup>b</sup>	somatic symptoms	<i>yes/no or true/false</i>	past week to day	patients and general population	yes
<b>Malaise Inventory</b> [42]	8	psychiatric morbidity	<i>yes/no</i>	'no specific time frame is defined, but the focus on recent state is evident'		no
<b>Manu</b> [43]	5	somatization disorder	<i>yes/no</i>			no
<b>MSPQ</b> [44]	13	heightened somatic and autonomic awareness	4 categories: <i>not at all to extremely, could not have been worse</i>	past week	designed specifically for chronic backache patients	no
<b>NSS</b> [45]	6	nonspecific symptoms for nonpsychotic morbidity	<i>present/not present</i>	at least three months	patients	yes
<b>Othmer &amp; DeSouza</b> [46]	7	somatization disorder	<i>yes/no</i>	lifetime	general population	yes
<b>PHQ</b> [47,48]	14	somatic symptoms	items 1-11, 7 categories: <i>not at all to all of the time</i> ; items 12-13, 7 categories: <i>0 times to 7+ times</i> ; item 14, 7 categories: <i>1 day to 7+ days</i>			no
<b>PHQ-15</b> [15,20]	15	probable somatoform disorder	3 categories: <i>not at all to bothered a lot</i>	past month	primary care patients	yes
<b>PILL</b> [49]	54	common physical symptoms and sensations	5 categories: <i>never or almost never to more than once every week</i>	lifetime		no
<b>PSC-17 (SUNYA)</b> [50]	17	psychosomatic symptoms	frequency, 5 categories: <i>daily to not a problem</i> ; intensity, 5 categories: <i>extremely bothersome to not a problem</i>	frequency scores	general and clinical populations; initially developed for muscle contractions headache patients	no

**Table 1.** Overview of the 40 symptom questionnaires and their properties<sup>a</sup> (continued)

Questionnaire	Items	Domain assessed	Scale	Time frame	Target population	Multiple languages
<b>PSC-51</b> [51]	51 or 55	somatization	4 categories: <i>not at all to most of the time</i>	past week	primary care patients	yes
<b>PSS</b> [52]	35	psychosomatic symptoms	frequency, 4 categories: <i>never to almost every day</i> ; disturbance, 3 categories: <i>none to strong</i>	past three months	children and adolescents	no
<b>PVPS</b> [53]	14 <sup>b</sup>	somatization	3 categories: <i>never occurred to frequently occurred</i>	past month	people of Vietnamese origin	yes
<b>RPSQ</b> [54]	26	somatization in irritable bowel syndrome patients	5 categories: <i>never or only once to every day</i>	past month	IBS patients	no
<b>R-SOMS-2</b> [55]	29	somatization	<i>yes/ no</i>	past two years	primary care patients	yes
<b>SCI</b> [56]	22	various physical symptoms	frequency, 5 categories: <i>never to daily</i> ; intensity, 5 categories: <i>no problems to extremely troublesome</i>	past month	general population	no
<b>SCL</b> [57]	11	common somatic complaints	5 categories: <i>almost never to quite often</i>	past month	children	yes
<b>SCL-90 SOM</b> [58]	12b	somatization	5 categories: <i>not at all to extremely</i>	past week	psychiatric medical out-patients/general population	yes
<b>SHC</b> [59]	29	subjective health complaints	severity, 4 categories: <i>not at all to serious</i> ; duration: <i>number of days</i>	past month	general population	yes
<b>SOMS-7</b> [60,61]	53	intervention effects in somatoform disorders	5 categories: <i>not at all to very severe</i>	past week	primary care patients	yes
<b>SSI</b> [62]	35	somatization	<i>yes/ no</i>	lifetime	primary care patients	yes
<b>SQ-48</b> [63]	7b	somatization	5 categories: <i>never to very often</i>	past week	clinical and non-clinical populations	yes
<b>Swartz</b> [64]	11	symptoms that potentially predict a diagnosis of DIS/ DSM-3 somatization disorder	<i>yes/ no</i>	lifetime	general population	no
<b>Syrian Symptom Checklist</b> [65]	19	psychosomatic symptoms; diagnose individuals, follow up treatment, evaluate treatment intervention	4 categories: <i>never to always</i>	past few weeks		no

**Table 1.** Overview of the 40 symptom questionnaires and their properties<sup>a</sup> (continued)

Questionnaire	Items	Domain assessed	Scale	Time frame	Target population	Multiple languages
<b>WHO-SSD [66]</b>	12	somatoform disorders	yes/ no	past six months	general population	yes
<b>YSR [67]</b>	9b	somatic complaints	3 categories: not true to very true or often true	past six months	11-18 yr. olds	yes
<b>von Zerssen [68]</b>	24	somatic complaints	4 categories: not at all to strong			no

<sup>a</sup>According to original questionnaire publication. <sup>b</sup>Subscale of a larger questionnaire

Abbreviations: 4DSQ: Four-Dimensional Symptom Questionnaire; ASR: Adult Self Report; BDS Checklist: Bodily Distress Syndrome Checklist; BSI: Bradford Somatic Inventory; BSI-6: Brief Symptom Inventory; Cambodian SSI: Cambodian Somatic Symptom and Syndrome Inventory; C-PSC: Children's Psychosomatic Symptom Checklist; CSI: Children's Somatization Inventory; FBL: Freiburger Beschwerden Liste (Freiburg Complaint List); GBB-24: Giessener Beschwerdebogen (Giessen Subjective Complaints List); GSL: Goldberg Symptom List; HEALTH-49: Hamburger Module zur Erfassung allgemeiner Aspekte psychosozialer Gesundheit für die therapeutische Praxis (Hamburger modules to measure general aspects of psychosocial health for therapeutic practice); ICD-10 Symptom List: International Classification of Diseases-10 Symptom List; MSPQ: Modified Somatic Perception Questionnaire; NSS: Nonspecific Symptom Screen; PHQ: Physical Health Questionnaire; PHQ-15: Patient Health Questionnaire; PILL: Pennebaker Inventory of Limbic Languidness; PSC-17 (SUNYA): Psychosomatic Symptom Checklist; PSC-51: Physical Symptom Checklist; PSS: Upitnika Psihosomatskih Simptoma (Psychosomatic Symptoms questionnaire); PVPS: Phan Vietnamese Psychiatric Scale; RPSQ: Recent Physical Symptoms Questionnaire; R-SOMS-2: Revised Screening for Somatoform Symptoms; SCI: Somatic Symptom Checklist Instrument; SCL: Somatic Complaint List; SCL-90 SOM: Symptom Checklist-90 somatization scale; SHC: Subjective Health Complaints Inventory; SOMS-7: Screening for Somatoform Symptoms; SSC: Syrian Symptom Checklist; SSI: Somatic Symptom Index; SQ-48: Symptom Questionnaire-48; WHO-SSD: World Health Organization-Screener for Somatoform Disorders; YSR: Youth Self Report

### Questionnaire content


Almost 500 descriptions of symptoms were used in the 40 symptom questionnaires. After combining descriptions referring to the same symptoms, we found 31 symptoms that were present in at least six questionnaires (table 2). The symptom of headache was most often included in the symptom questionnaires (70%). Other frequent symptoms included nausea/upset stomach (65%), shortness of breath/breathing trouble (58%), dizziness (55%), and (low) back pain/backache (55%). We grouped the symptoms into the above-mentioned clusters cardiopulmonary (including autonomic symptoms), gastrointestinal, musculoskeletal, and general symptoms. Remaining symptoms that did not fit into one of the clusters were classified under the category other symptoms. The latter category included symptoms of the sensory organs (e.g. blurred vision), neurological symptoms (e.g. numbness, amnesia), and symptoms of the urinary tract or sexual organs (e.g. pain during urination, pain during intercourse). Nine out of 40 questionnaires did not include at least one symptom from each symptom cluster (Othmer & DeSouza questionnaire, SQ-48, ASR, Manu questionnaire, NSS, Syrian Symptom Checklist, ICD-10 symptom list, RPSQ, HEALTH-49; figure 2).

**Table 2.** Overview of most included symptoms in the 40 symptom questionnaires. Symptom types that were included in  $\geq 6$  questionnaires are shown.

<b>SYMPTOMS</b>	<b>%</b>
<b>Cardiopulmonary/autonomic</b>	
Shortness of breath; breathing trouble; breathing difficulties	58
Chest pain; pains in heart or chest	43
Palpitations; heart palpitations; palpitations (heart pounding)	38
Sweating; sweating a lot; excessive perspiration	28
<b>Gastrointestinal</b>	
Nausea or upset stomach; nausea; nausea, feel sick; nauseated (sick to stomach)	65
Constipation; diarrhea (constipation); diarrhea; constipated (diarrhea); frequent diarrhea	55
Abdominal pain, stomachaches, stomach pain; pain in stomach	53
Bloating; bloating (gassy); belching	35
Vomiting; vomiting, throwing up; vomiting spells	30
Trouble swallowing; difficulty swallowing; difficulty swallowing/lump in throat	28
Heartburn; heartburn or acid regurgitation	23
Loss of appetite, poor appetite	23
Dry mouth	20
<b>General symptoms</b>	
Headaches	70
Dizziness	55
Fatigue; fatigability; feeling tired/little energy; tired; overtired	43
Fainting	25
Weakness; feeling weak	18
<b>Musculoskeletal</b>	
Back pain; pains in lower back; backache; low back trouble	55
Pain in extremities	33
Neck pain; neck or shoulder pain; pain or tension in neck and shoulders; neck/shoulder muscle ache; neck soreness; shoulder pain	28
Painful muscles; soreness of muscles	23
Joint pain	23
Heaviness in arms/legs	15
<b>Other</b>	
Numbness/tingling; numbness/tingling in individual body parts; numbness/tingling; numbness	43
Blurred vision; double/blurred vision; double vision	28
Irregular menstrual periods; painful menstruation; menstrual cramps/other problems with period	23
Pain during urination; difficulty urinating	18
Lump in throat	18
Amnesia; memory loss	18
Pain during intercourse; sexual problems; pain/problems sexual intercourse	15

Symptom clusters are based on previous studies [15-17].

The number of items within the questionnaires ranged from 5 to 78 items. Nineteen of the 40 (48%) questionnaires consisted of 15 items or fewer, as shown in figure 2. The time frames for symptom recall varied between lifetime and the previous week. However, most of the questionnaires inquired about symptoms of the past week or past month (figure 2). Eight out of 40 (20%) questionnaires required the symptoms to be medically unexplained.



**Figure 2.** Number of items and time frames for symptom recall. Black bars indicate questionnaires that do not contain symptoms from each symptom cluster. \*No information about time frames were available from these questionnaires. Abbreviations: 4DSQ: Four-Dimensional Symptom Questionnaire; ASR: Adult Self Report; BDS Checklist: Bodily Distress Syndrome Checklist; BSI: Bradford Somatic Inventory; BSI-6: Brief Symptom Inventory; Cambodian SSI: Cambodian Somatic Symptom and Syndrome Inventory; C-PSC: Children's Psychosomatic Symptom Checklist; CSI: Children's Somatization Inventory; FBL: Freiburger Beschwerden Liste (Freiburg Complaint List); GBB-24: Giessener Beschwerdebogen (Giessen Subjective Complaints List); GSL: Goldberg Symptom List; HEALTH-49: Hamburger Module zur Erfassung allgemeiner Aspekte psychosozialer Gesundheit für die therapeutische Praxis (Hamburger modules to measure general aspects of psychosocial health for therapeutic practice); ICD-10 Symptom List: International Classification of Diseases-10 Symptom List; MSPQ: Modified Somatic Perception Questionnaire; NSS: Nonspecific Symptom Screen; PHQ: Physical Health Questionnaire; PHQ-15: Patient Health Questionnaire; PILL: Pennebaker Inventory of Limbic Languidness; PSC-17 (SUNYA): Psychosomatic Symptom Checklist; PSC-51: Physical Symptom Checklist; PSS: Upitnika Psihosomatskih Simptoma (Psychosomatic Symptoms questionnaire); PVPS: Phan Vietnamese Psychiatric Scale; RPSQ: Recent Physical Symptoms Questionnaire; R-SOMS-2: Revised Screening for Somatoform Symptoms; SCI: Somatic Symptom Checklist Instrument; SCL: Somatic Complaint List; SCL-90 SOM: Symptom Checklist-90 somatization scale; SHC: Subjective Health Complaints Inventory; SOMS-7: Screening for Somatoform Symptoms; SSC: Syrian Symptom Checklist; SSI: Somatic Symptom Index; SQ-48: Symptom Questionnaire-48; WHO-SSD: World Health Organization-Screener for Somatoform Disorders; YSR: Youth Self Report

### **Internal consistency**

Most questionnaires had an acceptable internal consistency; except for the BSI-6 and the Malaise Inventory, for which an internal consistency of  $<0.70$  was found (table 3).

### **Factor structure**

The factor structure was investigated for some questionnaires, which referred to whether the items within a questionnaire clustered into meaningful factors. Factor analysis of the PHQ-15 revealed three factors: cardiopulmonary, gastrointestinal, and general pain/fatigue; which explained 46% of the variance. Factor analysis of the PSC-17 (SUNYA) resulted in one factor, explaining 67% of the variance; however another study reported a five factor solution with a total variance of 36%. Overall, most factor analyses of the questionnaires resulted in multiple factors, often including factors with symptoms originating from the same organ system (data not shown).

### **Test-retest reliability**

The test-retest reliability was reported for a few questionnaires, and referred to the variation of measurements at different time points, for the same individual (table 3). Stability within a short time interval ( $\leq$  two weeks) was found for the PVPS, RPSQ, Syrian Symptom Checklist, PHQ-15, SCL-90 SOM, PSC-17 (SUNYA), C-PSC, and the SOMS-2.

### **Validity**

Some of the questionnaires were correlated with other instruments that aimed to measure symptoms, FSS or somatization. Sometimes correlations with structured interviews were found, ranging from 0.52 to 0.80 (table 3). Correlations with the SCL-90 SOM were often investigated. For example, the correlation of the SOMS (time frame of two years) with the SCL-90 SOM was 0.44; however investigating another version of the SOMS in a much larger sample, the SOMS-7 (time frame of seven days, which is equal to the SCL-90 SOM) showed a correlation of 0.76. Furthermore, the SCL-90 SOM and 4DSQ showed a correlation of 0.82, and the correlation of the SCL-90 SOM and the PHQ-15 was 0.38 (table 3). Correlations of the symptom questionnaires with related concepts such as health anxiety and illness behavior were also investigated (table 3). Strong correlations with health anxiety were found for the PHQ-15 and SOMS-7; and less strong for the BSI. For illness behavior, significant correlations were found for the RPSQ, SCL-90 SOM, and the PHQ-15. As found by our literature search, the questionnaires that were most often validated were the PHQ-15 and SCL-90 SOM.

Table 3. Internal consistency, test-retest reliability and validity of 28<sup>a</sup> symptom questionnaires

Questionnaire	Internal consistency (Cronbach's $\alpha$ )		Test-retest reliability	Validity
	overall scale	subscales		
<b>4DSQ</b> [25]	0.80-0.84 [25]			correlation with SCL-90 SOM =0.82 (p<0.001) [25]
<b>BDS Checklist</b> [27]		0.82-0.86 [27]		
<b>BSI-6</b> [28]	=0.62 [69]			correlation with GHQ somatic symptoms =0.64 (British sample) and =0.55 (Pakistani sample) 29; WI (hypochochondria) no significant association [70]
<b>BSI</b> [29]				
<b>C-PSC</b> [32]	=0.83 [32]		at 1 week interval; Pearson product-moment correlation coefficient =0.90 [32]	
<b>CSI</b> [33]	0.90-0.92 [34,71,71]			
<b>FBL</b> [35]	0.95-0.97 [35,72]			
<b>GBB-24</b> [36]	=0.93 [36]	0.80-0.85 [36]		
<b>HEALTH-49</b> [38]	=0.82 [38]			
<b>Malaise Inventory</b> [42]	0.47-0.53 [42]			
<b>MSPQ</b> [44]	0.78-0.85 [44]			
<b>PHQ</b> [47,48]		0.60-0.88 [48]		
<b>PHQ-15</b> [15,20]	0.78-0.87 [20,73-76]		at 2 weeks interval: dichotomized PHQ score ( $\geq 3$ ) $\kappa$ coefficient =0.60; PHQ means of scores of 2 (severe somatic symptoms) intraclass correlation coefficient =0.83 [74]; at 2 weeks interval correlation =0.65 (p<0.001) [76]; at 1 month interval correlation =0.54 [77]	correlation with SCL-90 SOM =0.38 (p<0.001) [77]; proportion of variance R <sup>2</sup> explained by PHQ-15 for SF-20 scales: clinic visits =7.8; disability days =1.4 [20]; correlation with CID symptom count =0.52 [73]; correlation WI (hypochochondria) =0.50 (males), =0.55 (females), (both p<0.001) [78], =0.33 (p<0.001) [77]; correlation with nr. of symptoms reported in interview =0.63 (p≤0.001); nr. of medically unexplained symptoms assessed by general practitioner =0.63 (p≤0.001) [4]

**Table 3.** Internal consistency, test-retest reliability and validity of 28<sup>a</sup> symptom questionnaires (continued)

Questionnaire	Internal consistency (Cronbach's $\alpha$ )		Test-retest reliability	Validity
	overall scale	subscales		
<b>PILL</b> [49]	0.88-0.91 [49]			correlation with Cornell Medical Index (interview symptom count) =0.57 [49]
<b>PSC-17 (SUNYA)</b> [50]	0.74-0.81 [79,80]		at 1 week interval correlation =0.88 (p<0.0001); at 4 weeks interval =0.84 (p<0.0001) [50]	
<b>PSC-51</b> [51]	=0.88 [81]			
<b>PSS</b> [52]	0.90-0.93 [52]			
<b>PVPS</b> [53]	=0.90 [53]			
<b>RPSQ</b> [54]	=0.86 [54]		at 4 days interval: correlation =0.84 [53] at 2 weeks interval: =0.88 [54]	correlations with Cornell Medical Index (interview symptom count) =0.80; doctor visits (self-report) =0.50; self-rated health =0.31; BSI-18 (somatization subscale) =0.70 [54]
<b>R-SOMS-2</b> [55]	=0.83 [55]; 19-items version: KR-20 =0.88 [82]			Correlation with clinical symptom evaluation =0.63 [55]
<b>SCL</b> [57]	=0.83 [57]			
<b>SCL-90 SOM</b> [58]	0.70-0.90 [58,79,83-87]		at 1 week interval: test-retest coefficient =0.82 [58]	correlation highly structured interview by trained clinicians =0.73 [58]; Disease conviction scale =0.67 [88]; correlation with nr. of primary care consultations =0.27 (yr. before baseline) and =0.16 (yr. after baseline), (both p<0.001) [89]
<b>SHC</b> [59]	0.75-0.82 [90]	0.49-0.77 [90]		
<b>SOMS-2</b> [91]	for items 1-42, 0.87-0.89; for items 1-35, 0.84-0.87 [91]		35-items version: at 72 hours interval correlation =0.85; =0.71 (males); =0.93 (females); =0.97 (tinnitus patients); =0.91 (anxiety and depression patients); =0.75 (pain patients) [92]	group with somatization disorder (according to SOMS) had highest scores on WI (hypochoondria) [93]; correlation with SCL-90 SOM =0.44 [91]

Table 3. Internal consistency, test-retest reliability and validity of 28<sup>a</sup> symptom questionnaires (continued)

Questionnaire	Internal consistency (Cronbach's $\alpha$ )		Test-retest reliability	Validity
	overall scale	subscales		
<b>SOMS-7 [60]</b>	=0.92 (gender-unspecific items) [60]			correlation with DSM-4 somatization =0.66; SCL-90 SOM =0.76; WI (hypochondria) =0.46; Mark's scale (disability) =0.40 (all $p < 0.001$ ) [60]
<b>SQ-48 [63]</b>	=0.89 [63]			
<b>Syrian Symptom Checklist [65]</b>		0.56-0.85 [65]	at 7-10 days interval: Pearson's correlation coefficient =0.89 (males), =0.91 (females) [65]	
<b>YSR [67]</b>	0.76-0.77 [94]			

<sup>a</sup>Data were not available for all 40 questionnaires. The full table with validity data including information about study population and other psychometric properties is available from the authors. Abbreviations: 4DSQ: Four-Dimensional Symptom Questionnaire; BDS Checklist: Bodily Distress Syndrome Checklist; BSI: Bradford Somatic Inventory; BSI-6: Brief Symptom Inventory; BSI-18: Brief Symptom Inventory; CIDI: Composite International Diagnostic Interview; C-PSC: Children's Psychosomatic Symptom Checklist; CSI: Children's Somatization Inventory; FBL: Freiburger Beschwerden Liste (Freiburg Complaint List); GBB-24: Giessener Beschwerdebogen (Giessen Subjective Complaints List); GHQ: General Health Questionnaire; HEALTH-49: Hamburger Module zur Erfassung allgemeiner Aspekte psychosozialer Gesundheit für die therapeutische Praxis (Hamburger modules to measure general aspects of psychosocial health for therapeutic practice; MMPI: Minnesota Multiphasic Personality Inventory; MSPQ: Modified Somatic Perception Questionnaire; PHQ: Physical Health Questionnaire; PHQ-15: Patient Health Questionnaire; PLL: Pennebaker Inventory of Limbic Languidness; PSC-17 (SUNYA): Psychosomatic Symptom Checklist; PSC-51: Physical Symptom Checklist; PSS: Upitnika Psihosomatskih Simptoma (Psychosomatic Symptoms questionnaire); PVPS: Phan Vietnamese Psychiatric Scale; RPSQ: Recent Physical Symptoms Questionnaire; R-SOMS-2: Revised Screening for Somatoform Symptoms; SCL: Somatic Complaint List; SCL-90 SOM: Symptom Checklist-90 somatization scale; SF-20: Short-Form General Health survey-20; SHC: Subjective Health Complaints Inventory; SOMS-7: Screening for Somatoform Symptoms; SSC: Syrian Symptom Checklist; SSPS: Shalling Sifneos Personality Scale; SQ-48: Symptom Questionnaire-48; TAS: Toronto Alexithymia Scale; WI: Whiteley Index; YSR: Youth Self Report

## **Part 2: PhenX criteria**

### *Usability and burden to participants*

Questionnaires should be of relatively low burden to participants and investigators, and should therefore be both as short as possible and understandable to a wide range of persons. As shown in figure 2, the number of items within questionnaires ranged from 5 to 78, with 48% of the questionnaires being 15 items or shorter. All questionnaires assessed could be used by scientists with no specific expertise in the assessment of somatic symptoms, FSS or somatization, and no training is needed.

### *Relevance for future studies and to a variety of populations and regions*

We can assume that most symptoms included in these questionnaires will be relevant for future studies. As shown in table 1, some questionnaires are available in multiple languages, contributing to their relevance to a variety of regions. Most questionnaires are available in English; however, we were not able to find English versions for four questionnaires: the Syrian Symptom Checklist, von Zerssen questionnaire, SCI, and FBL. The Cambodian SSI is a questionnaire that is very region specific, with symptoms that will probably not be recognized in all regions of the world, such as “*Khyal attacks*.” Some of the questionnaires were developed for a specific population; the CSI, YSR, SCL, C-PSC, and the PSS were all developed for children or adolescents. The other questionnaires were either applicable to all age categories or the target population was not explicitly mentioned (table 1). The RPSQ is a questionnaire developed to investigate somatization in irritable bowel syndrome patients and therefore included no symptoms from the gastrointestinal cluster, because these symptoms are assumed to be present in these patients. Finally, it is worth mentioning that there are seven questionnaires that have gender specific or reproduction related items (e.g. painful menstruation or impotence). These are the Goldberg Symptom List, Othmer & DeSouza questionnaire, PHQ-15, PSC-51, SOMS-7, ICD-10 symptom list, and the SSI. In summary, there were five questionnaires that fulfilled all PhenX criteria. These were the ASR, BSI-6, PHQ-15, SCL-90 SOM, and the SQ-48.

## **DISCUSSION**

Of the 40 questionnaires included in this review, we believe many are unsuitable for use in large-scale studies. Many of these questionnaires did not contain the most relevant symptoms, were too lengthy, used a recall period that is too long,

or were inapplicable to a variety of populations and regions. In addition, some of the questionnaires were more extensively validated than others. Based on our criteria, there were two questionnaires that seem reasonably suitable for the use in large-scale studies. These were the PHQ-15 [15,20] and the SCL-90 SOM [58]. Both are not restricted to medically unexplained symptoms but concern symptoms in general, and both measure symptom severity. With the validity of these questionnaires well-established, these instruments would be suitable for use in future studies. These questionnaires are also relatively short, which makes them easy to use and of little burden to participants. No specific training is needed, making them usable by scientists who do not have expertise in this specific domain. Furthermore, they are available in multiple languages and contain relevant symptoms.

However, several questions remain. The first concerns which symptoms should be included in a questionnaire. We decided that questionnaires should not be restricted to medically unexplained symptoms, given the difficulties in establishing the causes of symptoms, especially in large-scale studies. Inquiring into symptoms in general is also in line with the new proposal for the psychiatric classification of patients with somatoform disorder, which abandons the distinction between symptoms that are medically explained and those that are not [95]. Furthermore, research has shown that a high total somatic symptom count, regardless of whether these are medically explained or unexplained, are important predictors of decreased health status and health-related quality of life [96].

Another aspect is which specific symptoms should be assessed. We reasoned that the proportion of instruments including a particular symptom would reflect expert knowledge and empirical data on the importance of that symptom for these questionnaires. Based on this reasoning, important symptoms are headaches, nausea/upset stomach, shortness of breath/breathing trouble, dizziness, and (low) back pain/backache. Both the PHQ-15 and the SCL-90 SOM contain these five symptoms. The importance and relevance of these symptoms for the process of somatization is underlined by a study showing which symptoms often remain medically unexplained in internal medicine outpatients. These were especially headaches, dizziness, constipation, back pain, abdominal pain, chest pain, numbness and impotence ( $\geq 75\%$  of these symptoms remained unexplained) [5]. Of the questionnaires with 15 items or less, the PHQ-15, the SCL-90 SOM, and the Swartz questionnaire inquired about at least five of these often unexplained symptoms. These questionnaires also included symptoms from all relevant symptom clusters, and thus covered an appropriate diversity of symptoms, while retaining a reasonable number of items.

The PHQ-15 and the SCL-90 SOM also differ in some aspects. A significant, but not very high correlation was found between the two questionnaires. Subsequently, only six symptoms overlap. This is probably due to the differences in the conceptual background of the symptom questionnaires. The PHQ-15 consists of the most prevalent symptoms in the US primary care [15], whereas the SCL-90 SOM consists of a subset of somatic symptoms associated with psychopathology [58]. Studies focused at somatization might thus preferably include the SCL-90 SOM, whereas studies interested in common somatic symptoms might preferably include the PHQ-15. Although the recent DSM-5 field trials to assess somatic symptoms used a shortened version of PHQ-15 97, showing that this questionnaire is also commonly used to assess somatization.

Another difference is that the PHQ-15 contains items related to reproduction, in contrast to the SCL-90 SOM. These reproduction related items (menstruation problems and pain or problems during sexual intercourse) would make the PHQ-15 less applicable to children. Furthermore, although the PHQ-15 is well validated in both sexes, 'menstruation problems' should be ignored by men when filling out the questionnaire; and a negative answer to 'pain or problems during sexual intercourse' can have multiple interpretations.

A second remaining question concerns the timeframe. Most of the questionnaires enquired about symptoms in the last month or a shorter time period, with the PHQ-15 covering the past month and the SCL-90 SOM covering the past week. Answers to questionnaires that enquire about symptoms in a longer time period (e.g. the ASR with six months or the Swartz questionnaire with lifetime) are probably prone to recall bias [21], which could result in a less reliable instrument. On the other hand, a short timeframe might detect fluctuations in symptom levels that are not meaningful for symptom measurement. The ideal time frame for symptom questionnaires remains to be investigated, based on an appropriate balance between the risk of excessive recall bias and the detection of meaningful fluctuations. A related issue concerns the answer modalities, which are typically based on frequency for the questionnaires covering longer time windows and both frequency and severity for the shorter time windows. Severity may be a more appropriate and reliable answering scale, compared to frequency of symptoms. The PHQ-15 and SCL-90 SOM both measure symptom severity with respectively a 3-points scale and a 5-points scale. Further research could determine the optimal number of response categories for these questionnaires.

A third question concerns the relevance to a variety of age groups. A questionnaire should be preferably suitable for all age groups. It is not known whether the PHQ-15 and SCL-90 SOM are also suitable for children or adolescents. The PHQ-15 has four symptoms overlapping with the YSR, a questionnaire specific for

children. As mentioned earlier, the PHQ-15 contains two symptoms about reproductive function which would be inapplicable to children. The SCL-90 SOM has three symptoms overlapping with the YSR, but no items related to reproduction.

### **Internal consistency, factor structure, test-retest reliability and validity**

Both the PHQ-15 and SCL-90 SOM showed acceptable internal consistency and factor analyses resulted in meaningful factors. Results of test-retest reliability indicated that the results of the PHQ-15 and SCL-90 SOM are relatively stable within a short time period. Intercorrelations of the PHQ-15 and SCL-90 SOM with other measures of somatization showed some overlap with these, indicating they measure a comparable construct. Additionally, the PHQ-15 and SCL-90 SOM showed some overlap with other related constructs, such as health anxiety and illness behavior. Correlations with health anxiety and illness behavior are especially relevant, as these constructs are part of the new DSM proposal for the diagnosis of somatic symptom disorder [98]. Although some overlap is expected, high correlations of symptom questionnaires with other constructs can indicate a lack of discrimination.

In addition to these psychometric properties, other areas could be further assessed. Sensitivity to change of the questionnaires could be evaluated, in particular if the questionnaire will be used in longitudinal studies. Especially in anticipation of the DSM-5, it would be important to assess the sensitivity and specificity of the questionnaires for the new diagnostic criteria for somatic symptom disorder. Assessments from an item response theory (IRT) approach are also important to evaluate. For example, with IRT it is possible to investigate whether test scores have the same meaning across different groups. This examination of differential item functioning (DIF) for subgroups can be useful in questionnaire evaluation of, for example, general and clinical populations or different ethnic populations [99]. Another example is that IRT can be used to translate scores of one instrument into the other, using a set of anchor items, which are similar items in different questionnaires, that function similarly across questionnaires. Questionnaire scores are then equated, making the individual scores comparable [100]. This could enhance the comparability between studies, even if different questionnaires are used.

### **Limitations**

Although many efforts were taken to identify all symptom questionnaires currently available, there is still a chance that some questionnaires were missed. Furthermore, it is possible that not all validation studies of the questionnaires were included in this study. The main goal of this study was to identify all the relevant questionnaires and not to identify all the validation studies of these

questionnaires. Therefore, the search term used for the literature search in this review was not constructed to identify all the available validation studies. Another limitation concerning the validity of the questionnaires must be acknowledged: in order to evaluate validity, a gold standard is required. For the assessment of symptoms, a gold standard is not available and the questionnaires' validity can therefore not be compared to a gold standard. Additionally, some characteristics of specific symptom questionnaires were unavailable. Some questionnaires may also be available in more languages than reported here, as our search was not targeted at identifying all available versions of the questionnaires. It was not possible to establish the well-establishment (i.e. used repeatedly over time and coming from highly regarded sources) of the questionnaires, as we could not determine whether every questionnaire was often used or came from a highly regarded source.

## **CONCLUSION**

We believe this is the first study that systematically reviewed somatic symptom questionnaires and evaluated them for use in large-scale studies. We provided an overview of which symptom questionnaires are available and suitable. By providing this review, we hope to end the use of different symptom instruments in different studies, which makes comparisons between studies difficult, if not impossible. Although the recommendation of a symptom list was mainly intended for large-scale studies, this could also apply to other types of studies. Ultimately, this will contribute to the harmonization of studies and thereby contribute to knowledge of the prevalence of somatic symptoms or FSS.

## REFERENCES

1. Rhodes VA, Watson PM. Symptom distress—The concept: Past and present. *Semin Oncol Nurs*. 1987;3(4):242-247.
2. McAteer A, Elliott AM, Hannaford PC. Ascertaining the size of the symptom iceberg in a UK-wide community-based survey. *Br J Gen Pract*. 2011;61(582):e1-11.
3. Bruusgaard D, Tschudi-Madsen H, Ihlebaek C, Kamaleri Y, Natvig B. Symptom load and functional status: Results from the ullensaker population study. *BMC Public Health*. 2012;12:1085.
4. Körber S, Frieser D, Steinbrecher N, Hiller W. Classification characteristics of the patient health questionnaire-15 for screening somatoform disorders in a primary care setting. *J Psychosom Res*. 2011;71(3):142-147.
5. Kroenke K, Mangelsdorff AD. Common symptoms in ambulatory care: Incidence, evaluation, therapy, and outcome. *Am J Med*. 1989;86(3):262-266.
6. Lipowski ZJ. Somatization: The concept and its clinical application. *Am J Psychiatry*. 1988;145(11):1358-1368.
7. Steinbrecher N, Koerber S, Frieser D, Hiller W. The prevalence of medically unexplained symptoms in primary care. *Psychosomatics*. 2011;52(3):263-271.
8. Jackson JL, Passamonti M. The outcomes among patients presenting in primary care with a physical symptom at 5 years. *J Gen Intern Med*. 2005;20(11):1032-1037.
9. Rosmalen JGM. The way forward: A case for longitudinal population-based studies in the field of functional somatic syndromes. *J Psychosom Res*. 2010;68(5):399-401.
10. Gureje O, Simon GE, Ustun TB, Goldberg DP. Somatization in cross-cultural perspective: A world health organization study in primary care. *Am J Psychiatry*. 1997;154(7):989-995.
11. Barsky AJ, Borus JF. Functional somatic syndromes. *Ann Intern Med*. 1999;130(11):910-921.
12. Kroenke K, Spitzer RL, deGruy FV, et al. Multisomatoform disorder - an alternative to undifferentiated somatoform disorder for the somatizing patient in primary care. *Arch Gen Psychiatry*. 1997;54(4):352-358.
13. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. *Arch Gen Psychiatry*. 2005;62(8):903-910.
14. Nettleton S. 'I just want permission to be ill': Towards a sociology of medically unexplained symptoms. *Soc Sci Med*. 2006;62(5):1167-1178.
15. Kroenke K, Spitzer RL, deGruy FV, 3rd, Swindle R. A symptom checklist to screen for somatoform disorders in primary care. *Psychosomatics*. 1998;39(3):263-272.
16. Fink P, Toft T, Hansen MS, Ornbol E, Olesen F. Symptoms and syndromes of bodily distress: An exploratory study of 978 internal medical, neurological, and primary care patients. *Psychosom Med*. 2007;69(1):30-39.
17. Rosmalen JGM, Tak LM, de Jonge P. Empirical foundations for the diagnosis of somatization: Implications for DSM-5. *Psychol Med*. 2010:1-10.
18. Kroenke K. Physical symptom disorder: A simpler diagnostic category for somatization-spectrum conditions. *J Psychosom Res*. 2006;60(4):335-339.
19. Rief W, Mewes R, Martin A, Glaesmer H, Braehler E. Evaluating new proposals for the psychiatric classification of patients with multiple somatic symptoms. *Psychosom Med*. 2011;73(9):760-768.
20. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: Validity of a new measure for evaluating the severity of somatic symptoms. *Psychosom Med*. 2002;64(2):258-266.

21. Leiknes KA, Finset A, Moum T, Sandanger I. Methodological issues concerning lifetime medically unexplained and medically explained symptoms of the composite international diagnostic interview: A prospective 11-year follow-up study. *J Psychosom Res.* 2006;61(2):169-179.
22. Simon GE, Gureje O. Stability of somatization disorder and somatization symptoms among primary care patients. *Arch Gen Psychiatry.* 1999;56(1):90-95.
23. Hamilton CM, Strader LC, Pratt JG, et al. The PhenX toolkit: Get the most from your measures. *Am J Epidemiol.* 2011;174(3):253-260.
24. Hayes AF. Assessing and quantifying reliability. In: *Statistical methods for communication science.* Mahwah, NJ: Lawrence Erlbaum Associates.; 2005:103.
25. Terluin B, van Marwijk HW, Ader HJ, et al. The four-dimensional symptom questionnaire (4DSQ): A validation study of a multidimensional self-report questionnaire to assess distress, depression, anxiety and somatization. *BMC Psychiatry.* 2006;6:34.
26. Achenbach TM, Rescorla LA. *Manual for the ASEBA adult forms & profiles.* Burlington, VT: University of Vermont, Research Center for Children, Youth, & Families.; 2003.
27. Budtz-Lilly A, Fink P, Ørnbøl E, et al. Measuring bodily distress in a primary care population: The use of a new patient questionnaire (submitted). 2012.
28. Derogatis LR, Melisaratos N. The brief symptom inventory: An introductory report. *Psychol Med.* 1983;13(3):595-605.
29. Mumford DB. Somatic sensations and psychological distress among students in Britain and Pakistan. *Soc Psychiatry Psychiatr Epidemiol.* 1989;24(6):321-326.
30. Mumford DB, Bavington JT, Bhatnagar KS, Hussain Y, Mirza S, Naraghi MM. The Bradford Somatic Inventory - a multiethnic inventory of somatic symptoms reported by anxious and depressed-patients in Britain and the Indo-Pakistan subcontinent. *British Journal of Psychiatry.* 1991;158:379-386.
31. Hinton DE, Kredlow MA, Bui E, Pollack MH, Hofmann SG. Treatment change of somatic symptoms and cultural syndromes among Cambodian refugees with PTSD. *Depression Anxiety.* 2011;4(2).
32. Wisniewski JJ, Naglieri JA, Mulick JA. Psychometric properties of a children's psychosomatic symptom checklist. *J Behav Med.* 1988;11(5):497-507.
33. Walker LS, Garber J, Greene JW. Somatization symptoms in pediatric abdominal pain patients: Relation to chronicity of abdominal pain and parent somatization. *J Abnorm Child Psychol.* 1991;19(4):379-394.
34. Garber J, Walker LS, Zeman J. Somatization symptoms in a community sample of children and adolescents: Further validation of the children's somatization inventory. *Psychological Assessment: A Journal of Consulting and Clinical Psychology.* 1991;3(4):588-595.
35. Fahrenberg J. Somatic complaints in the German population. *J Psychosom Res.* 1995;39(7):809-817.
36. Braehler E, Schumacher J, Braehler C. First all-Germany standardization of the brief form of the Gissen Complaints Questionnaire GBB-24. *Psychother Psychosom Med Psychol.* 2000;50(1):14-21.
37. Herman SL, Lester D. Physical symptoms of stress, depression, and suicidal ideation in high school students. *Adolescence.* 1994;29(115):639-641.
38. Rabung S, Harfst T, Kawski S, Koch U, Wittchen HU, Schulz H. Psychometric analysis of a short form of the "Hamburg Modules for the Assessment of Psychosocial Health" (HEALTH-49). *Z Psychosom Med Psychother.* 2009;55(2):162-179.

39. World Health Organization. Somatisation disorder. in: *The ICD-10 classification of mental and behavioural disorders. diagnostic criteria for research*. Geneva: World Health Organization; 1993.
40. Khoo EM, Mathers NJ, McCarthy SA, Low WY. Somatisation disorder and its associated factors in multiethnic primary care clinic attenders. *Int J Behav Med*. 2012;19(2):165-173.
41. Kellner R. A symptom questionnaire. *J Clin Psychiatry*. 1987;48(7):268-274.
42. Rodgers B, Pickles A, Power C, Collishaw S, Maughan B. Validity of the malaise inventory in general population samples. *Soc Psychiatry Psychiatr Epidemiol*. 1999;34(6):333-341.
43. Manu P, Lane TJ, Matthews DA, Escobar JL. Screening for somatization disorder in patients with chronic fatigue. *Gen Hosp Psychiatry*. 1989;11(4):294-297.
44. Main CJ. The modified somatic perception questionnaire (MSPQ). *J Psychosom Res*. 1983;27(6):503-514.
45. Srinivasan TN, Suresh TR. The nonspecific symptom screening method. detection of nonpsychotic morbidity based on nonspecific symptoms. *Gen Hosp Psychiatry*. 1991;13(2):106-114.
46. Othmer E, DeSouza C. A screening test for somatization disorder (hysteria). *Am J Psychiatry*. 1985;142(10):1146-1149.
47. Spence JT, Helmreich RL, Pred RS. Impatience versus achievement strivings in the type A pattern: Differential effects on students' health and academic achievement. *J Appl Psychol*. 1987;72(4):522-528.
48. Schat AC, Kelloway EK, Desmarais S. The physical health questionnaire (PHQ): Construct validation of a self-report scale of somatic symptoms. *J Occup Health Psychol*. 2005;10(4):363-381.
49. Pennebaker JW. *The psychology of physical symptoms*. New York: Springer-Verlag; 1982.
50. Attanasio V, Andrasik F, Blanchard EB, Arena JG. Psychometric properties of the SUNYA revision of the psychosomatic symptom checklist. *J Behav Med*. 1984;7(2):247-257.
51. de Waal MWM, Arnold IA, Spinhoven P, Eekhof JAH, van Hemert AM. The reporting of specific physical symptoms for mental distress in general practice. *J Psychosom Res*. 2005;59(2):89-95.
52. Vulić-Prtorić A. Upitnik psihosomatskih simptoma za djecu i adolescente - procjena valjanosti. *Suvremena Psihologija*. 2005;8(2):211-227.
53. Phan T, Steel Z, Silove D. An ethnographically derived measure of anxiety, depression and somatization: The phan vietnamese psychiatric scale. *Transcult Psychiatry*. 2004;41(2):200-232.
54. MacLean EW, Palsson OS, Turner MJ, Whitehead WE. Development and validation of new disease-specific measures of somatization and comorbidity in IBS. *J Psychosom Res*. 2012.
55. Fabiao C, Silva MC, Barbosa A, Fleming M, Rief W. Assessing medically unexplained symptoms: Evaluation of a shortened version of the SOMS for use in primary care. *BMC Psychiatry*. 2010;10:34.
56. Bohman H, Jonsson U, Paaren A, von Knorring L, Olsson G, von Knorring AL. Prognostic significance of functional somatic symptoms in adolescence: A 15-year community-based follow-up study of adolescents with depression compared with healthy peers. *BMC Psychiatry*. 2012;12:90.
57. Jellesma FC, Rieffe C, Terwogt MM. The somatic complaint list: Validation of a self-report questionnaire assessing somatic complaints in children. *J Psychosom Res*. 2007;63(4):399-401.
58. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The hopkins symptom checklist (HSCL): A self-report symptom inventory. *Behav Sci*. 1974;19(1):1-15.
59. Ursin H, Endresen IM, Ursin G. Psychological factors and self-reports of muscle pain. *Eur J Appl Physiol Occup Physiol*. 1988;57(3):282-290.

60. Rief W, Hiller W. A new approach to the assessment of the treatment effects of somatoform disorders. *Psychosomatics*. 2003;44(6):492-498.
61. Rief W, Hiller W. Das screening für somatoforme störungen SOMS [the screening for somatoform symptoms]. manual zum fragebogen. 2nd revised edition ed. Bern: Huber-Verlag; 2008.
62. Escobar JI, Rubio-Stipec M, Canino G, Karno M. Somatic symptom index (SSI): A new and abridged somatization construct. prevalence and epidemiological correlates in two large community samples. *J Nerv Ment Dis*. 1989;177(3):140-146.
63. Carlier I, Schulte-Van Maaren Y, Wardenaar K, et al. Development and validation of the 48-item symptom questionnaire (SQ-48) in patients with depressive, anxiety and somatoform disorders. *Psychiatry Res*. 2012;30;200(2-3):904-10. doi: 10.1016/j.psychres.2012.07.035.
64. Swartz M, Hughes D, George L, Blazer D, Landerman R, Bucholz K. Developing a screening index for community studies of somatization disorder. *J Psychiatr Res*. 1986;20(4):335-343.
65. Rudwan SJ. A checklist of the syrian psychological psychosomatic symptoms. *Journal of the Social Sciences*. 2000;28(4):113-138.
66. Phillips KA, Fallon BA, King S. Somatoform and factitious disorders and malingering measures. In: Rush AJ, Jr., First MB, Blacker D, Rush AJ, Jr., First MB, Blacker D, eds. *Handbook of psychiatric measures* (2nd ed.). Arlington, VA US: American Psychiatric Publishing, Inc; 2008:559-585.
67. Gledhill J, Garralda ME. Functional symptoms and somatoform disorders in children and adolescents: The role of standardised measures in assessment. *Child and Adolescent Mental Health*. 2006;11(4):208-214.
68. Ladwig KH, Marten-Mittag B, Lacruz ME, Henningsen P, Creed F, MONICA KORA Investigators. Screening for multiple somatic complaints in a population-based survey: Does excessive symptom reporting capture the concept of somatic symptom disorders? findings from the MONICA-KORA cohort study. *J Psychosom Res*. 2010;68(5):427-437.
69. Galdon MJ, Dura E, Andreu Y, et al. Psychometric properties of the brief symptom inventory-18 in a spanish breast cancer sample. *J Psychosom Res*. 2008;65(6):533-539.
70. Chakraborty K, Avasthi A, Kumar S, Grover S. Psychological and clinical correlates of functional somatic complaints in depression. *Int J Soc Psychiatry*. 2012;58(1):87-95.
71. Meesters C, Muris P, Ghys A, Reumerman T, Rooijmans M. The children's somatization inventory: Further evidence for its reliability and validity in a pediatric and a community sample of dutch children and adolescents. *J Pediatr Psychol*. 2003;28(6):413-422.
72. Jensen H, Salazar Z, Aguilar I. Adaptación castellana de la 'lista de síntomas orgánicos de friburgo'. *Avances en Psicología Clínica Latinoamericana*. 1986;4:97-113.
73. Interian A, Allen LA, Gara MA, Escobar JI, Diaz-Martinez AM. Somatic complaints in primary care: Further examining the validity of the patient health questionnaire (PHQ-15). *Psychosomatics*. 2006;47(5):392-398.
74. van Ravesteijn H, Wittkampf K, Lucassen P, et al. Detecting somatoform disorders in primary care with the PHQ-15. *Ann Fam Med*. 2009;7(3):232-238.
75. Ros Montalban S, Comas Vives A, Garcia-Garcia M. Validation of the spanish version of the PHQ-15 questionnaire for the evaluation of physical symptoms in patients with depression and/or anxiety disorders: DEPRE-SOMA study. *Actas Esp Psiquiatr*. 2010;38(6):345-357.
76. Han C, Pae CU, Patkar AA, et al. Psychometric properties of the patient health questionnaire-15 (PHQ-15) for measuring the somatic symptoms of psychiatric outpatients. *Psychosomatics*. 2009;50(6):580-585.

77. Gulec MY, Gulec H, Simsek G, Turhan M, Sunbul EA. Psychometric properties of the turkish version of the patient health questionnaire-somatic, anxiety, and depressive symptoms. *Compr Psychiatry*. 2012;53(5):623-629.
78. Lee S, Ng KL, Ma YL, Tsang A, Kwok KP. A general population study of the chinese whiteley-7 index in hong kong. *J Psychosom Res*. 2011;71(6):387-391.
79. Bagby RM, Taylor GJ, Atkinson L. Alexithymia: A comparative study of three self-report measures. *J Psychosom Res*. 1988;32(1):107-116.
80. Chibnall JT, Tait RC. The psychosomatic symptom checklist revisited: Reliability and validity in a chronic pain population. *J Behav Med*. 1989;12(3):297-307.
81. de Waal MW, Arnold IA, Spinhoven P, Eekhof JA, Assendelft WJ, van Hemert AM. The role of comorbidity in the detection of psychiatric disorders with checklists for mental and physical symptoms in primary care. *Soc Psychiatry Psychiatr Epidemiol*. 2009;44(1):78-85.
82. Fabiao C, Barbosa A, Fleming M, Silva C. Screening of somatization disorder in primary health care. results from a pilot study. *Acta Med Port*. 2008;21(4):319-328.
83. Holi MM, Sammallahti PR, Aalberg VA. A finnish validation study of the SCL-90. *Acta Psychiatr Scand*. 1998;97(1):42-46.
84. Schmitz N, Hartkamp N, Brinshwitz C, Michalek S. Computerized administration of the symptom checklist (SCL-90-R) and the inventory of interpersonal problems (IIP-C) in psychosomatic outpatients. *Psychiatry Res*. 1999;87(2-3):217-221.
85. Schmitz N, Hartkamp N, Brinshwitz C, Michalek S, Tress W. Comparison of the standard and the computerized versions of the symptom check list (SCL-90-R): A randomized trial. *Acta Psychiatr Scand*. 2000;102(2):147-152.
86. Schmitz N, Hartkamp N, Kiuse J, Franke GH, Reister G, Tress W. The symptom check-list-90—R (SCL-90—R): A german validation study. *Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care & Rehabilitation*. 2000;9(2):185-193.
87. Van Kamp I, Stoop LA. De hopkins symptom checklist bij epidemiologisch onderzoek. *Ned Tijdschr Psychol*. 1986;41(8):369-373.
88. Ciccone DS, Just N, Bandilla EB. Non-organic symptom reporting in patients with chronic non-malignant pain. *Pain*. 1996;68(2-3):329-341.
89. Tomenson B, McBeth J, Chew-Graham CA, et al. Somatization and health anxiety as predictors of health care use. *Psychosom Med*. 2012;74(6):656-664.
90. Eriksen HR, Ihlebaek C, Ursin H. A scoring system for subjective health complaints (SHC). *Scand J Public Health*. 1999;27(1):63-72.
91. Rief W, Schäfer S, Fichter MM. SOMS: Ein screening-verfahren zur identifizierung von personen mit somatoformen störungen. *Diagnostica*. 1992;38(3):228-241.
92. Rief W, Hiller W, Goebel G, Fichter MM. Zur zeitlichen stabilität der angaben hypochondrischer und somatoformer symptome. *Diagnostica*. 1995;41(2):172-180.
93. Hiller W, Rief W, Fichter MM. Further evidence for a broader concept of somatization disorder using the somatic symptom index. *Psychosomatics*. 1995;36(3):285-294.
94. Janssens KA, Oldehinkel AJ, Rosmalen JGM. Parental overprotection predicts the development of functional somatic symptoms in young adolescents. *J Pediatr*. 2009;154(6):918-23.e1.
95. American Psychiatric Association. APA DSM-5 development. <http://www.dsm5.org>. Updated 2012. Accessed November/09, 2012.
96. Creed FH, Davies I, Jackson J, et al. The epidemiology of multiple somatic symptoms. *J Psychosom Res*. 2012;72(4):311-317.

97. Narrow WE, Clarke DE, Kuramoto SJ, et al. DSM-5 field trials in the united states and canada, part ill: Development and reliability testing of a cross-cutting symptom assessment for DSM-5. *Am J Psychiatry*. 2013;170(1):71-82.
98. Dimsdale J, Creed F, DSM-V Workgroup on Somatic Symptom Disorders. The proposed diagnosis of somatic symptom disorders in DSM-V to replace somatoform disorders in DSM-IV - a preliminary report. *J Psychosom Res*. 2009;66(6):473-476.
99. Reise SP, Waller NG. Item response theory and clinical measurement. *Annual Review of Clinical Psychology*. 2009;5:27-48.
100. Fischer HF, Tritt K, Klapp BF, Fliege H. How to compare scores from different depression scales: Equating the patient health questionnaire (PHQ) and the ICD-10-symptom rating (ISR) using item response theory. *Int J Methods Psychiatr Res*. 2011;20(4):203-214.

**APPENDIX** Abbreviations questionnaires

---

4DSQ	Four-Dimensional Symptom Questionnaire
ASR	Adult Self Report
BDS Checklist	Bodily Distress Syndrome Checklist
BSI	Bradford Somatic Inventory
BSI-6	Brief Symptom Inventory
Cambodian SSI	Cambodian Somatic Symptom and Syndrome Inventory
C-PSC	Children's Psychosomatic Symptom Checklist
CSI	Children's Somatization Inventory
FBL	Freiburger Beschwerden Liste (Freiburg Complaint List)
GBB-24	Giessener Beschwerdebogen (Giessen Subjective Complaints List)
GSL	Goldberg Symptom List
HEALTH-49	Hamburger Module zur Erfassung allgemeiner Aspekte psychosozialer Gesundheit für die therapeutische Praxis (Hamburger modules to measure general aspects of psychosocial health for therapeutic practice)
ICD-10 Symptom List	International Classification of Diseases-10 Symptom List
MSPQ	Modified Somatic Perception Questionnaire
NSS	Nonspecific Symptom Screen
PHQ	Physical Health Questionnaire
PHQ-15	Patient Health Questionnaire
PILL	Pennebaker Inventory of Limbic Languidness
PSC-17 (SUNYA)	Psychosomatic Symptom Checklist
PSC-51	Physical Symptom Checklist
PSS	Upitnika Psihosomatskih Simptoma (Psychosomatic Symptoms questionnaire)
PVPS	Phan Vietnamese Psychiatric Scale
RPSQ	Recent Physical Symptoms Questionnaire
R-SOMS-2	Revised Screening for Somatoform Symptoms
SCI	Somatic Symptom Checklist Instrument
SCL	Somatic Complaint List
SCL-90 SOM	Symptom Checklist-90 somatization scale
SHC	Subjective Health Complaints Inventory
SOMS-7	Screening for Somatoform Symptoms
SSI	Somatic Symptom Index
SQ-48	Symptom Questionnaire-48
WHO-SSD	World Health Organization-Screener for Somatoform Disorders
YSR	Youth Self Report

---

